Loading…
Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy
Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical...
Saved in:
Published in: | Oftalmologicheskiĭ zhurnal. 2022-03, Vol.96 (1), p.30-36 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 36 |
container_issue | 1 |
container_start_page | 30 |
container_title | Oftalmologicheskiĭ zhurnal. |
container_volume | 96 |
creator | Ponomarchuk, Vira S Korol, A. R. Umanets, M. M. |
description | Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy. Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy. Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02). Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery. |
doi_str_mv | 10.31288/oftalmolzh20223036 |
format | article |
fullrecord | <record><control><sourceid>doaj_cross</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_eecf1ea8c5904917b6efb45edd70530e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_eecf1ea8c5904917b6efb45edd70530e</doaj_id><sourcerecordid>oai_doaj_org_article_eecf1ea8c5904917b6efb45edd70530e</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2256-afb56f21ad3eedd8bf2a68ed20668603ad555bdb97f16466b324df1ab8a2ea2f3</originalsourceid><addsrcrecordid>eNplkN1KAzEQhYMoWGqfwJu8wGp-Ntn0Ukr9gYI3er1MNjNtZLcp2SjUp3et4o03c2Bm-M7hMHYtxY2WyrnbRAX6IfWfOyWU0kLbMzZTtVSVa2pxzmZCaFEJ25hLthjH6IWQjbO6djPWrYliB92RJ-Jlh3xIIVLEwMcC20kGLLsUvq_je95Orz0vGaEMuC-cUuaHnPpImKHED-QhgscSO56nuU8HKLvjFbsg6Edc_Oqcvd6vX1aP1eb54Wl1t6k6pYytgLyxpCQEjRiC86TAOgxKWOus0BCMMT74ZUPS1tZ6repAErwDhaBIz9nTDzckeGsPOQ6Qj22C2J4WKW9byFO2HlvEjiSC68xS1EvZeIvkazPZNsJogRNL_7C6nMYxI_3xpGhPtbf_a9dfLTN7-Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy</title><source>DOAJ Directory of Open Access Journals</source><creator>Ponomarchuk, Vira S ; Korol, A. R. ; Umanets, M. M.</creator><creatorcontrib>Ponomarchuk, Vira S ; Korol, A. R. ; Umanets, M. M. ; SI ; The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine ; SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"</creatorcontrib><description>Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy. Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy. Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02). Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery.</description><identifier>ISSN: 0030-0675</identifier><identifier>EISSN: 2412-8740</identifier><identifier>DOI: 10.31288/oftalmolzh20223036</identifier><language>eng</language><publisher>Ukrainian Society of Ophthalmologists</publisher><subject>intravitreal aflibercept ; proliferative diabetic retinopathy ; vitrectomy</subject><ispartof>Oftalmologicheskiĭ zhurnal., 2022-03, Vol.96 (1), p.30-36</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,2102,27924,27925</link.rule.ids></links><search><creatorcontrib>Ponomarchuk, Vira S</creatorcontrib><creatorcontrib>Korol, A. R.</creatorcontrib><creatorcontrib>Umanets, M. M.</creatorcontrib><creatorcontrib>SI</creatorcontrib><creatorcontrib>The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine</creatorcontrib><creatorcontrib>SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"</creatorcontrib><title>Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy</title><title>Oftalmologicheskiĭ zhurnal.</title><description>Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy. Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy. Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02). Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery.</description><subject>intravitreal aflibercept</subject><subject>proliferative diabetic retinopathy</subject><subject>vitrectomy</subject><issn>0030-0675</issn><issn>2412-8740</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNplkN1KAzEQhYMoWGqfwJu8wGp-Ntn0Ukr9gYI3er1MNjNtZLcp2SjUp3et4o03c2Bm-M7hMHYtxY2WyrnbRAX6IfWfOyWU0kLbMzZTtVSVa2pxzmZCaFEJ25hLthjH6IWQjbO6djPWrYliB92RJ-Jlh3xIIVLEwMcC20kGLLsUvq_je95Orz0vGaEMuC-cUuaHnPpImKHED-QhgscSO56nuU8HKLvjFbsg6Edc_Oqcvd6vX1aP1eb54Wl1t6k6pYytgLyxpCQEjRiC86TAOgxKWOus0BCMMT74ZUPS1tZ6repAErwDhaBIz9nTDzckeGsPOQ6Qj22C2J4WKW9byFO2HlvEjiSC68xS1EvZeIvkazPZNsJogRNL_7C6nMYxI_3xpGhPtbf_a9dfLTN7-Q</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Ponomarchuk, Vira S</creator><creator>Korol, A. R.</creator><creator>Umanets, M. M.</creator><general>Ukrainian Society of Ophthalmologists</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>20220301</creationdate><title>Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy</title><author>Ponomarchuk, Vira S ; Korol, A. R. ; Umanets, M. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2256-afb56f21ad3eedd8bf2a68ed20668603ad555bdb97f16466b324df1ab8a2ea2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>intravitreal aflibercept</topic><topic>proliferative diabetic retinopathy</topic><topic>vitrectomy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ponomarchuk, Vira S</creatorcontrib><creatorcontrib>Korol, A. R.</creatorcontrib><creatorcontrib>Umanets, M. M.</creatorcontrib><creatorcontrib>SI</creatorcontrib><creatorcontrib>The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine</creatorcontrib><creatorcontrib>SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"</creatorcontrib><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Oftalmologicheskiĭ zhurnal.</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ponomarchuk, Vira S</au><au>Korol, A. R.</au><au>Umanets, M. M.</au><aucorp>SI</aucorp><aucorp>The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine</aucorp><aucorp>SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy</atitle><jtitle>Oftalmologicheskiĭ zhurnal.</jtitle><date>2022-03-01</date><risdate>2022</risdate><volume>96</volume><issue>1</issue><spage>30</spage><epage>36</epage><pages>30-36</pages><issn>0030-0675</issn><eissn>2412-8740</eissn><abstract>Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy. Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy. Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02). Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery.</abstract><pub>Ukrainian Society of Ophthalmologists</pub><doi>10.31288/oftalmolzh20223036</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0030-0675 |
ispartof | Oftalmologicheskiĭ zhurnal., 2022-03, Vol.96 (1), p.30-36 |
issn | 0030-0675 2412-8740 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_eecf1ea8c5904917b6efb45edd70530e |
source | DOAJ Directory of Open Access Journals |
subjects | intravitreal aflibercept proliferative diabetic retinopathy vitrectomy |
title | Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T21%3A58%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20the%20modified%20staged%20method%20of%20surgical%20treatment%20for%20proliferative%20diabetic%20retinopathy&rft.jtitle=Oftalmologicheski%C4%AD%20zhurnal.&rft.au=Ponomarchuk,%20Vira%20S&rft.aucorp=SI&rft.date=2022-03-01&rft.volume=96&rft.issue=1&rft.spage=30&rft.epage=36&rft.pages=30-36&rft.issn=0030-0675&rft.eissn=2412-8740&rft_id=info:doi/10.31288/oftalmolzh20223036&rft_dat=%3Cdoaj_cross%3Eoai_doaj_org_article_eecf1ea8c5904917b6efb45edd70530e%3C/doaj_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2256-afb56f21ad3eedd8bf2a68ed20668603ad555bdb97f16466b324df1ab8a2ea2f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |